
|Articles|October 27, 2008
Dusa Pharmaceuticals abandons Levulan PDT
Wilmington, Mass. - Dusa Pharmaceuticals has stopped developing Levulan photo dynamic therapy for acne, after mid-stage trials failed to show statistically significant results.
Advertisement
Wilmington, Mass.
- Dusa Pharmaceuticals has stopped developing Levulan photo dynamic therapy for acne, after mid-stage trials failed to show statistically significant results, Reuters reports.
The treatment combination, called Levulan PDT, is approved for the treatment of actinic keratoses of the face and scalp. It is also used off-label to treat photodamage.
Advertisement
Latest CME
Advertisement
Advertisement














